Detalhe da pesquisa
1.
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Blood
; 128(7): 971-81, 2016 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27335278
2.
Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.
Mol Cancer Ther
; 16(8): 1669-1679, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28428443
3.
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
J Control Release
; 220(Pt B): 758-65, 2015 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26385168